@reibergerthomas.bsky.social
Professor of Hepatology @MedUni_Wien Director CD-Lab for #PortalHypertension & #LiverFibrosis Adjunct PI @cemm-vienna.bsky.social Head #KFG #MOTION funded by @lbg.ac.at Scientific Secretary @bavenocoop.bsky.social
🚨 How do ⚡injury mechanisms and 🕑 disease states from health ➡️ fibrosis ➡️ regression shape the NO–sGC–cGMP pathway in chronic #liver #cirrhosis?
Check out our comprehensive assessment of regulation patterns of this pivotal pathway here:
rdcu.be/exM9Z
@reibergerthomas.bsky.social
🌍 #WorldHepatitisDay #2025
🇦🇹 contributions to understanding & Elimination of #Hepatitis
1⃣ #HBV-ART in #HIV 🔗 t.ly/6TXxR
2⃣ Curing #HCV in #HIV 🔗 t.ly/FiLPq
3⃣ Eliminate #HCV in 🇦🇹AT 🔗 t.ly/CBw3o
4⃣ Followup after #HCV cure 🔗 t.ly/KvSrs
Chronische #Lebererkrankungen im Fokus: @mathiasjachs.bsky.social, #ResearcherOfTheMonth der #MedUniWien, hat gezeigt, dass Pfortaderhochdruck schmerzfrei durch Messung der Organsteifigkeit diagnostiziert werden kann.
Mehr im Video in gesamter Länge! 🎥➡️ https://bit.ly/3G6VoGC
REMEMBERING PROFESSOR JAUME BOSCH
President of Bavneo @bavenocoop.bsky.social
Friend and Mentor to many
🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
🎂 30Y of .mp3 🎵
created @ Frauenhofer Institute 🔗 t.ly/f6A1t
by 🧑🎓 Karlheinz Brandenburg 🔗 t.ly/8vojd
🙏 for good vibes when i grew up
♻️ Napster 🔗 t.ly/lqPRP
⏯️ Winamp 🔗 t.ly/_sR05
Drs. @LorenzBALCAR of @meduniwien.ac.at & @MartaTONON identify a #cirrhosis population with #ascites at particular risk for shortterm #PortalHypertension complications
@jhepatology.bsky.social Reports: t.ly/iCvXY
Ascites #Grade3 + 🚨 MELD ≥12 or 🚨 Na ≤135
➡️ good candidates for #TIPS
Drs. @LukasHARTL and @MarleneHINTERSTEININGER of @meduniwien.ac.at showed in @CGH @AGA that
adding the #Vasopressin #ADH Biomarker #Copeptin to the MELD score improves prognostication of patients with #cirrhosis #ACLD
📖 the full study 🔗 t.ly/11GOg
@easlnews.bsky.social @bavenocoop.bsky.social
🌍⏩ #MedUniVienna ranks 66th in #ClinicalMedicine and is among the top 200 in the US News Global #UniversityRanking.
🔝📌 In the @timeshighered.bsky.social Impact Ranking 2025, MedUni Vienna is 10th worldwide in "Good Health and Well-Being".
Details ⬇️
The #HEPEX Hepatic Experimental Lab at @meduniwien.ac.at and @cemm.oeaw.ac.at works on Disease-driving #Pathomechanisms in #Liver #Fibrosis & #PortalHypertension
🕸️ #Macrophages in #Fibrosis Resolution
🤖 #MachineLearning & #Pathomics in #LiverHistology
🦠 #Gut-Liver-Axis
🩸 #Anticoagulation
@who.int has set Elimination of
🦠 #ViralHepatitis #B #C as a global goal for 2030
#Prisons remain a Hot ♨️ Spot for #HepC #HCV
In Vienna 🇦🇹 we focus on the incarcerated risk population
and offer onsite screening and treatment
@worldhepalliance.bsky.social
@easlnews.bsky.social
We kicked off the week with Roger Kamm (@mitdeptofbe.bsky.social) for a #CeMMinar on brain neurovascular models & its applications to modeling drug & toxin transport. Thanks to Roger for the great insights & hosts @lderooij.bsky.social & @ar-abdelfattah.bsky.social
16.06.2025 13:37 — 👍 2 🔁 2 💬 0 📌 0
🇦🇹 Austrian GI/Liver Meeting 2025
3 rising 🌟 stars of our research group #MOTION
@crgmotion.bsky.social @meduniwien.ac.at presented
posters on hot 🔥 topics in #Hepatology
- Clinical Course of #NAD non-acute decompensation
- #SpleenStiffness in #PortalHypertension
- #Ultrasound Elastography in MASLD
Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades - Gastrointestinal Endoscopy www.giejournal.org/article/S001...
12.06.2025 21:15 — 👍 0 🔁 0 💬 0 📌 0
📈 Activation of🩸#Vasopressin System in #Cirrhosis tries to compensate for 🫀 #hemodynamic & 💧#sodium #fluid abnormalities
Drs. HARTL & HINTERSTEININGER of @meduniwien.ac.at
in 🤝with efclif.com show in📕 #CGH
🔗 t.ly/joCs5
▶️ #Vasopressin biomarker #COPEPTIN predicts #ACLF in cirrhosis
#LiverResearch team #HEPEX-Lab @meduniwien.ac.at is affiliated w Center for Molecular Medicine @cemm.oeaw.ac.at
@KatjaSommer #Gut-Liver-Axis
@VladTaru #LiverFailure #ACLF
@BenHofer #Cirrhosis #Recompensation
@KathiBonitz restaurative #Macrophages
@ThomasSorz #AI Patho Spatial Transcritomics
Study by our #Liver #Team @meduniwien.ac.at
and @MedHochschuleHannover
Minimal residual ascites 3 months after #TIPS implantation implicates worse clinical outcome in patients with #liver #cirrhosis
published in @jhepatology.bsky.social #Reports
🔗 sciencedirect.com/science/arti...
#LiverSky
📘 JOURNAL OF HEPATOLOGY #JHEPATOL
@jhepatology.bsky.social
is the flagshipjournal of 🇪🇺 #EASL @easlnews.bsky.social
📈 Impact Factor of 26.8 ➡️ 2.1% 🔝Percentile
Consider to submit your #Liver #Research
🔗 www.journal-of-hepatology.eu
@heinerwedemeyer.bsky.social
@docberza.bsky.social
#LiverSky
What is shown here?
01.06.2025 13:41 — 👍 1 🔁 1 💬 0 📌 0
🚨 #LiverSky
interested in #Cirrhosis and #PortalHypertension
➡️ Read the #Baveno VII Consensus
🔗 t.ly/1P7Ta
Get Ready and Register for the #Baveno VIII Consensus
📆 27-28 MARCH 2026
🔗 baveno8.org
@bavenocoop.bsky.social
@easlnews.bsky.social @aasldnews.bsky.social
⚠️ #Hepatitis B Elimination
@easlnews.bsky.social @who.int @lancetgastrohep.bsky.social
😑 73% met #WHO criterion of ≤0.5% HBsAg prevalence
😑 67% have universal #HBV birth vaccinations
☹️ Suboptimal #WHO diagnosis coverage target of 60%
😱 no country met #HBV treatment target
⚠️ #Hepatitis C Elimination
@easlnews.bsky.social @who.int
@lancetgastrohep.bsky.social
😑 not all countries have national HCV action plans
☹️ 36% have (partial) restrictions on curative #HCV treatments
😑 30% met HCV #WHO diagnosis coverage target of 60%
☹️ only 15% met HCV #WHO treatment target
#GI #Endoscopy #IBD #CU #Colitis #CD #Crohn
❓which endoscopic score to you use❓
#MES #Mayo Endoscopic Score
#UCEIS Ulcerative Colitis Endoscopic Index of Activity
#Rutgeerts score for Grading Ileum Pathology
#PICcaSSo score for mucosal & vascular architecture
@AGA @CGH
🔗 tinyurl.com/s4xuwy93
☘️ #Celtics ☘️
15.05.2025 05:31 — 👍 0 🔁 0 💬 0 📌 0
In the (early) pathophysiology of MASLD the LSEC and microvascular alterations are key. Lanifibranor improves LSEC capillarisation and dysfunction! tinyurl.com/x37637j4
#AntwerpHepatology #AntwerpHypothesis @rautoupe.bsky.social @svenfrancque.bsky.social
@easlnews.bsky.social Studio during #EASLcongress 2025 in Amsterdam with discussions on therapeutic targets in decompensated #cirrhosis involving @debbieshawcross.bsky.social and representatives of @boehringerglobal.bsky.social and @genfit.bsky.social
12.05.2025 19:39 — 👍 5 🔁 1 💬 0 📌 0
What a pleasure to meet many friends and colleagues during @easlnews.bsky.social #EASLcongress 2025 in Amsterdam.
A special last minute surprise was Prof. Tung-Hung Su from Taiwan.
That’s a wrap on #EASLCongress2025! 💙 Thanks to all 7,742 attendees from 119 countries and all those who made this event possible! 🌍
See you in Barcelona on 27–30 May 2026!
Look back at the unforgettable moments easl.smugmug.com/EASL-Congres...
Best of slide decks: easlcampus.eu/Documents/be...
@easlnews.bsky.social #HBV CPG# Guidance on
🛑 Stopping Nucleoside Analogon (NUC) Therapy in #HBV
(1) No immunusppression / no advanced liver disease (fibrosis)
(2) HBV-DNA suppression (< 3 years)
(3) HBsAg-Quant <1000 in Caucasians / <100 in Asians
